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Low-Frequency Coding Variants
at 6p21.33 and 20q11.21 Are Associated
with Lung Cancer Risk in Chinese Populations
Guangfu Jin,1,2,10 Meng Zhu,1,10 Rong Yin,3 Wei Shen,1 Jia Liu,1 Jie Sun,1 Cheng Wang,1
Juncheng Dai,1 Hongxia Ma,1 Chen Wu,4 Zhihua Yin,5 Jiaqi Huang,6 Brandon W. Higgs,6 Lin Xu,3
Yihong Yao,6 David C. Christiani,7 Christopher I. Amos,8 Zhibin Hu,1,2,3,11 Baosen Zhou,5,11
Yongyong Shi,9,11 Dongxin Lin,4,11 and Hongbing Shen1,2,11,*
Genome-wide association studies have successfully identified a subset of common variants associated with lung cancer risk. However,
these variants explain only a fraction of lung cancer heritability. It has been proposed that low-frequency or rare variants might have
strong effects and contribute to the missing heritability. To assess the role of low-frequency or rare variants in lung cancer development,
we analyzed exome chips representing 1,348 lung cancer subjects and 1,998 control subjects during the discovery stage and subse-
quently evaluated promising associations in an additional 4,699 affected subjects and 4,915 control subjects during the replication
stages. Single-variant and gene-based analyses were carried out for coding variants with a minor allele frequency less than 0.05.We iden-
tified three low-frequency missense variants in BAT2 (rs9469031, c.1544C>T [p.Pro515Leu]; odds ratio [OR] ¼ 0.55, p ¼ 1.28 3 1010),
FKBPL (rs200847762, c.410C>T [p.Pro137Leu]; OR ¼ 0.25, p ¼ 9.79 3 1012), and BPIFB1 (rs6141383, c.850G>A [p.Val284Met]; OR ¼
1.72, p ¼ 1.793 107); these variants were associated with lung cancer risk. rs9469031 in BAT2 and rs6141383 in BPIFB1were also asso-
ciated with the age of onset of lung cancer (p¼ 0.001 and 0.006, respectively). BAT2 and FKBPL at 6p21.33 and BPIFB1 at 20q11.21 were
differentially expressed in lung tumors and paired normal tissues. Gene-based analysis revealed that FKBPL, in which two independent
variants were identified, might account for the associationwith lung cancer risk at 6p21.33. Our results highlight the important role low-
frequency variants play in lung cancer susceptibility and indicate that candidate genes at 6p21.33 and 20q11.21 are potentially biolog-
ically relevant to lung carcinogenesis.Lung cancer is among the most frequently diagnosed
cancers and is the leading cause of cancer-related death
worldwide.1 Tobacco smoking is the major cause of lung
cancer, whereas genetic factors determine individual pre-
disposition to lung cancer. We and others have identified
a subset of loci that are associated with lung cancer risk
through genome-wide association studies (GWASs).2–10
These variants generally occur at a high frequency (minor
allele frequency [MAF] > 0.05) in populations, and the
effect of single variants is modest (odds ratios [ORs] ¼
1.1–1.4 for risk alleles). To date, these known common
loci explain only a small fraction of the familial risk of
lung cancer, and the remaining missing heritability is
uncertain.
GWASs mainly focus on common proxy SNPs that are
based on the HapMap Project. Most low-frequency
(defined here as a MAF of 0.5%–5%) and rare (MAF <
0.5%) variants were not previously evaluated in most
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variants might have strong effects and might contribute
to the missing heritability of complex diseases, including
cancer. Supporting this hypothesis is that several genes
containing known low-frequency or rare missense variants
are associated with various cancers: ATM (MIM: 607585),
BRIP1 (MIM: 605882), CHEK2 (MIM: 604373), and PALB2
(MIM: 610355) for breast cancer;11 RAD51D (MIM:
602954) and BRIP1 for ovarian cancer;12,13 and HOXB13
(MIM: 604607) for prostate cancer.14 More recently,
Wang et al. implicated two large-effect, low-frequency var-
iants—rs11571833 (c.9976A>T [p.Lys3326*]; GenBank:
NM_000059) in BRCA2 (MIM: 600185) and rs17879961
(c.470T>C [p.Ile157Thr]; GenBank: NM_007194.3) in
CHEK2 (MIM: 604373)—in susceptibility to lung cancer
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Sequencing is an ideal approach for investigating low-
frequency or rare variants but has been limited so far
because of its cost. The Illumina HumanExome Beadchip
(referred to as ‘‘exome chip’’ hereafter) platform has thus
been developed to capture low-frequency or rare variants
in coding regions on the basis of genetic variants discov-
ered from the whole-exome sequencing of >12,000 indi-
viduals. Recently, several groups have validated this
platform as an effective complementary approach for
determining the genetic basis of complex diseases or
traits.16–18 To address the role of low-frequency or rare var-
iants in the development of lung cancer, we generated and
analyzed exome-chip data for 1,348 lung cancer subjects
and 1,998 control subjects and subsequently evaluated
promising associations in an additional 4,699 affected sub-
jects and 4,915 control subjects. As a result, we identified
three low-frequency missense variants in BAT2 (MIM:
142580), FKBPL, and BPIFB1, which are associated with
lung cancer risk in Chinese populations.
A three-stage case-control analysis was conducted, and
the characteristics of the subjects are summarized in Table
S1. In the discovery stage, 1,348 lung cancer subjects and
1,998 control subjects were recruited from Nanjing and
the surrounding areas; some of these individuals were also
included in our previous GWAS.7 In the first replication
stage (replication I), 1,115 affected subjects and 1,246 con-
trol subjects were recruited according to the same standards
as those used in the discovery stage during 2009–2013. In
the second replication stage (replication II), a total of
3,584 affected subjects and 3,669 control subjects were re-
cruited from northern China; 2,466 affected subjects and
2,423 control subjectswere fromBeijing, and1,118 affected
subjects and 1,246 control subjects were from Shenyang.
All of these affected subjects were collected from local
hospitals and were histopathologically or cytologically
confirmed as having lung cancer by at least two patholo-
gists. All control subjectswere cancer-free subjects receiving
a routine physical examination in a local hospital or partic-
ipants in a community screening of noncommunicable dis-
eases. All subjects were unrelated ethnic Han Chinese and
gave informed consent at recruitment. Smoking informa-
tion was obtained via interviews; individuals who had
smoked an average of one or more cigarettes per day for at
least 1 year before recruitment were defined as current
smokers, whereas smokers who had quit more than 1 year
before recruitment were considered former smokers; other-
wise, subjects were considered non-smokers. Current and
former smokers were divided into light and heavy smokers
according to themedian smoking level of 25 pack years (the
number of packs of cigarettes smoked per daymultiplied by
the number of years a person has smoked) among control
subjects. This study was approved by the institutional re-
view board of each participating institution.
We successfully genotyped 1,348 lung cancer subjects
and 1,998 control subjects by using the Illumina
HumanExome Beadchip system and found a total of
247,870 variants. The lung cancer and control subjectsThe Amwere genotyped together, and the technicians were blinded
to the sample status. Genotypes were called by Illumina
GenomeStudio software, and the selected variants were
re-called by zCall.19 Systematic quality control of the raw
genotyping datawas performed to filter unqualified genetic
variants and samples (Figure S1). A total of 175,447 variants
were excluded from subsequent analysis because they (1)
were mitochondrial variants or were located on the X or Y
chromosome, (2) had duplicate variants on the chip, (3)
were monomorphic in our study subjects, (4) had a call
rate of <95%, or (5) presented a p value< 1 3 104 in a
Hardy-Weinberg equilibrium test among the control sub-
jects. A total of 7 affected subjects and 16 control subjects
were excluded because they (1) had an overall genotyping
rate of <95%, (2) were duplicates or showed familial rela-
tionships (PI_HAT> 0.25), or (3) had an extreme heterozy-
gosity rate more than 6 SDs from the mean. Population
outliers and stratification were detected with a method
based on principal-component analysis. As shown in
Figure S2, no individuals were excluded as outliers, and
the affected and control subjects were geneticallymatched.
Weassessed genotyping consistencyon thebasis of 37 repli-
cate samples and found an overall concordance rate of
99.98%. Moreover, 1,369 subjects were also scanned with
an Affymetrix Genome-Wide Human SNP Array 6.0 in a
previous GWAS,7 and the concordance rate was 99.93%
for 6,660 overlapping variants after quality control. Accord-
ingly, 6 samples and 50 variants with a concordance rate
<95% were also excluded. Finally, 72,423 variants in
1,341 affected subjects and 1,982 control subjects were re-
tained for further association analysis.
In this study, wemainly focused on the low-frequency or
rare variants with MAFs between 0.1% and 5% when we
could call at least six copies of the minor allele in our study
samples. On the basis of the following items, we then
selected promising variants for further genotyping in the
replication stages: (1) variants were in nonsynonymous
or splice sites, (2) the single-variant association p value
was less than 0.001, (3) variant calling was visually in-
spected with a clear genotyping cluster, and (4) only one
variant was selected when multiple variants were in link-
age disequilibrium (LD; r2 R 0.5). On the basis of the re-
sults from the discovery stage, we genotyped 21 variants
in the replication I stage by using SNPscan technology
(GeneSky). To obtain positive control samples of minor ge-
notypes for low-frequency or rare variants, we included
192 discovery-stage samples in the replication I stage to
ensure the presence of at least two heterozygotes or minor
homozygotes, and the concordance rate was 99.4%. In the
replication II stage, genotyping was performed with the
TaqMan system (Applied Biosystems). Positive and nega-
tive control subjects were included in each 384-well plate
for quality control. The average concordance rate between
duplicate samples was >99%. Genotyping was performed
by technicians who were blinded to sample status.
Assuming an additive genetic model, we performed a
single-variant association analysis by using a logisticerican Journal of Human Genetics 96, 832–840, May 7, 2015 833
regression model as implemented in PLINK.20 At the dis-
covery stage, we carried out principal-component analysis
with EIGENSOFT21 to determine ancestry and population
stratification on the basis of 4,604 autosomal ancestry-
informative markers included on the exome chips. The
top principal component was significant (p ¼ 0.03), and
we included it (together with age, gender, and smoking
level by pack years) in the logistic regression model as a co-
variate when we estimated ORs and 95% confidence inter-
vals (CIs). We also used the logistic score test22 and the
Firth bias-corrected logistic likelihood-ratio test23 to assess
the association results for rare or low-frequency variants.
At the replication stages, we used age, gender, and smoking
level as covariates. We performed joint analysis to combine
the discovery and replication stages and used age, gender,
smoking level, and study stage as covariates. We applied
conditional analysis to test the independence of genetic
variants in each region and used the predefined variant(s)
as covariate(s). We performed two gene-based tests using
nonsynonymous and splice-site variants with a MAF <
5% (n ¼ 43,782): a simple burden test24 and a sequence
kernel association test (SKAT).25 The SKAT was imple-
mented in the sequence kernel association optimal test
(SKAT-O).26 We defined statistical significance by using
the Bonferroni correction and set the exome-wide signifi-
cance levels at 2 3 107 for single-variant analysis (0.05/
250,000 variants) and 2.83 3 106 for gene-based analysis
(8,840 genes 3 2 tests). The quantile-quantile plot was
generated with R v.2.3.1, and regional plots were created
with LocusZoom.27 We annotated variants according to
GENCODE v.7 coding transcripts,28 dbNSFP v.2.0,29 or
documentation files obtained from the Illumina Product
Support Files.
We obtained the normalized expression data and clinical
information for lung cancer samples from The Cancer
Genome Atlas (TCGA) on July 8, 2014. A total of 107 paired
samples (lung tumor with adjacent normal tissues) were
used in this analysis. The paired t test was used to test
whether gene expression differed between tumors and
the adjacent normal tissues. Seventy-nine out of the 107
individuals had clinical follow-up information and were
included in the survival analysis. The mRNA expression
ratio of the tumor and adjacent normal tissues was calcu-
lated with read counts normalized to RNA sequencing
(RNA-seq) by expectation maximization (RSEM). The indi-
viduals were divided into two groups on the basis of the
median value of the expression ratio for each gene. The
Kaplan-Meier method and the log-rank test were used for
evaluating the association between gene expression and
survival.
After quality control, 72,423 polymorphic variants were
included in the exome chip (29.2% of 247,870 variants)
performed on 3,323 Chinese Han subjects. The detailed
distributions of these variants are summarized in Table
S2. In the single-variant association analysis, the quan-
tile-quantile plot revealed a goodmatch between the distri-
butions of the observed and expected p values (Figure S3).834 The American Journal of Human Genetics 96, 832–840, May 7, 2A small genomic-control inflation factor (l) of 1.04, which
decreased to 1.01 after the removal of variants that showed
a cluster of association signals at 6p22.2–6p21.31, indi-
cated a low possibility of false-positive associations result-
ing from population stratification. However, at the
discovery stage, we did not find any variants associated
with lung cancer risk at our predefined exome-wide signif-
icance level (p< 23 107) (Figure S4), which was probably
due to limited statistical power, especially for low-fre-
quency or rare variants (Figure S5).
We then conducted a two-stage replication study for
promising nonsynonymous or splice-site variants with a
MAF from 0.1% to 5%. At the replication I stage, we geno-
typed 21 variants with clear cluster plots (Figure S6) in
1,115 lung cancer subjects and 1,246 control subjects
(Table S3). As a result, four variants with a p value <0.05
at the replication I stage showed consistent associations
with variants found at the discovery stage (Table S3). At
the replication II stage, we genotyped these four variants
and found that the associations were consistent for all
four variants and that two of them had a p value <0.05
(Table S3). When combining the results from the discovery
and replication stages, we found three low-frequency,
missense variants at BAT2 (rs9469031, c.1544C>T
[p.Pro515Leu]; OR ¼ 0.55, p ¼ 1.28 3 1010), FKBPL
(rs200847762, c.410C>T [p.Pro137Leu]; OR ¼ 0.25, p ¼
9.79 3 1012), and BPIFB1 (rs6141383, c.850G>A
[p.Val284Met]; OR ¼ 1.72, p ¼ 1.79 3 107) to be signifi-
cantly associated with lung cancer risk and to have p values
less than 2 3 107 (Table 1). We also found a promising
HIST1H1E variant (rs2298090, c.455A>G [p.Lys152Arg];
OR ¼ 0.51) with a combined p value of 2.95 3 107. The
MAFs of these four variants were also less than 0.05 in
other populations, and two of the variants (rs9469031
and rs2298090) were polymorphic but not associated
with lung cancer risk according to in silico replication in
populations of European ancestry (Table S4).15
We then analyzed the relationships between the four
identified variants and the onset ages of the lung cancer
case subjects. We observed that rs9469031 and rs6141383
were significantly associated with onset age after adjusting
for gender and smoking level (p¼ 0.001 and 0.006, respec-
tively; Figure 1). Lung cancer subjects carrying the protec-
tive allele (T) of rs9469031 had a higher onset age (62.125
10.56 years) than those without the protective allele
(59.52 5 10.18 years), and those with the risk allele (A)
of rs6141383 had a lower onset age (58.63 5 9.23 years)
than those without the risk allele (59.64 5 10.23 years).
In addition, we did not find significantly different associa-
tions between the subgroups divided by age, gender, smok-
ing, or histology (Table S5).
We then carefully evaluated genetic variants in the flank-
ing regions (1 Mb upstream or downstream) of rs9469031,
rs200847762, rs2298090, and rs6141383. As shown in
Figure S7, four variants, including the identified variant
(rs200847762) at FKBPL, had a lower p values than that
of rs9469031, one variant (rs138097862) failed to be015
Table 1. The Identified Low-Frequency Variants Associated with Lung Cancer Risk
Chr Gene Variant ID
Major/Minor
Allele Variant Stage Affected Subjectsa Control Subjectsa
MAF
OR (95% CI)b p ValuecAffected Subjects Control Subjects
6p21.33 BAT2 rs9469031 C/T c.1544C>T (p.Pro515Leu)
(GenBank: NM_004638)
discovery 1,291/50/0 1,840/140/2 0.019 0.036 0.52 (0.37–0.73) 1.54 3 104
replication I 1,066/42/6 1,150/85/10 0.024 0.042 0.61 (0.44–0.83) 1.71 3 103
replication II 3,429/78/1 3,502/129/0 0.011 0.018 0.62 (0.46–0.84) 1.71 3 103
combinedd – – – – 0.55 (0.46–0.66) 1.28 3 1010
6p21.33 FKBPL rs200847762 G/A c.410C>T (p.Pro137Leu)
(GenBank: NM_022110)
discovery 1,329/12/0 1,908/73/1 0.004 0.019 0.21 (0.11–0.39) 1.84 3 106
replication I 1,094/6/0 1,206/32/1 0.003 0.014 0.19 (0.08–0.46) 2.24 3 104
replication II 3,566/15/0 3,642/23/1 0.002 0.003 0.66 (0.34–1.28) 0.216
combinedd – – – – 0.25 (0.17–0.37) 9.80 3 1012
6p22.2 HIST1H1E rs2298090 A/G c.455A>G (p.Lys152Arg)
(GenBank: NM_005321)
discovery 1,325/16/0 1,904/77/1 0.006 0.020 0.32 (0.19–0.56) 6.16 3 105
replication I 1,073/27/1 1,178/54/3 0.013 0.024 0.56 (0.36–0.87) 9.80 3 103
replication II 3,385/44/0 3,492/59/0 0.006 0.008 0.67 (0.44–1.02) 6.03 3 102
combinedd – – – – 0.51 (0.39–0.66) 2.95 3 107
20q11.21 BPIFB1 rs6141383 G/A c.850G>A (p.Val284Met)
(GenBank: NM_033197)
discovery 1,277/62/2 1,934/48/0 0.025 0.012 2.00 (1.36–2.95) 4.80 3 104
replication I 1,065/42/3 1,209/31/0 0.022 0.013 1.68 (1.07–2.63) 2.30 3 102
replication II 3,374/133/0 3,368/87/0 0.019 0.013 1.64 (1.24–2.17) 6.20 3 104
combinedd – – – – 1.72 (1.40–2.10) 1.79 3 107
Abbreviations are as follows: Chr, chromosomal region; MAF, minor allele frequency; CI, confidence interval.
aMajor homozygote/heterozygote/minor homozygote.
bDerived from the logistic regression model after adjustment for age, gender, pack years of smoking, and the top principal component (for the discovery stage only) under the assumption of an additive genetic model.
cDerived from the logistic regression model adjusting for age, gender, pack years of smoking, and the top principal component (for the discovery stage only) under the assumption of an additive genetic model.
dThe joint analysis was performed to combine the discovery and replication stages with age, gender, smoking level, and study stage as covariates.
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Figure 1. The Relationships between rs9469031 in BAT2 and
rs6141383 in BPIFB1 and Age of Onset in Individuals with Lung
Cancer
Individuals carrying rs9469031 CT/TT genotypes (A), which were
associated with a decreased risk of lung cancer, were older at onset
(62.12 5 10.56 years) than those with CC genotypes (59.52 5
10.18 years, p ¼ 0.001 after adjustment for gender and smoking
levels). Individuals carrying rs6141383 GA/AA genotypes (B),
which were associated with an increased risk of lung cancer,
were younger at onset (58.635 9.23 years) than those withGG ge-
notypes (59.64 5 10.23 years, p ¼ 0.006 after adjustment for
gender and smoking levels).replicated at the replication stages, and two variants
(rs117160266, c.353A>G [p.Asn28Ser], in FKBPL and
rs9469057, c.205G>C [p.Ala8Pro], in HSPA1L [MIM:
140559]) were in strong LD with rs9469031 (r2 ¼ 0.96
and 0.99, respectively) (Table S6). The associations of these
two highly correlated variants were abolished after condi-
tioning on rs9469031 (Table S6). We did not find any asso-
ciations that were more prominent than those of
rs200847762, rs2298090, and rs6141383 for their respec-
tive regions (Figure S7). There were no other variants in
strong LD (r2 > 0.5) with these three variants as genotyped
on the exome chip (Table S6).
We further conducted gene-based analysis by using the
SKAT-O and burden tests for variants with a MAF < 0.05
and found a significant association between FKBPL and
lung cancer risk in both tests (p ¼ 1.29 3 109 and 2.0 3
1010, respectively; Table 2). As shown in Figure S8, three
coding variants of FKBPL were included in the gene-based
analysis. In the single-variant analysis, the variants
rs200847762 and rs117160266 (tagged by rs9469031 at836 The American Journal of Human Genetics 96, 832–840, May 7, 2BAT2 with r2 ¼ 0.96) were in low LD (r2 < 0.1) and were
independently associated with lung cancer risk (Table 1
and Table S6). After we conditioned on either of these
two variants, the significance of FKBPL was partially
decreased, and the signal was abolished after we condi-
tioned on both variants (Table 2). These results suggest
that the gene-based signal of FKBPL is driven by
rs200847762 and rs117160266. We also replicated the
association between FKBPL and lung cancer risk in the
gene-based analyses of the replication stages (p < 0.001)
by using genotyping data for rs200847762 and
rs9469031 (Table 2).
The missense variant rs9469031 in BAT2 is located at
6p21.33, which is part of the human leukocyte antigen
(HLA) region that was initially identified as a lung cancer
susceptibility region and was tagged by common variants
(rs3117582 and rs3131379) in GWASs involving subjects
of European ancestry.6 The association was confirmed in
some follow-up studies,30,31 but not all of these studies
involved populations of European ancestry.32 However,
studies based on East Asian populations consistently failed
to replicate the association7,10 because none of the identi-
fied variants in European populations are polymorphic in
East Asian populations. Notably, although the initially
identified variant, rs3117582, was not associated with
lung cancer risk in African Americans, the minor allele of
missense variant rs2736158 (c.4140G>C [p.Gly1285Ala]
in exon 16) in BAT2 was associated with a decreased risk
of squamous cell lung cancer (OR ¼ 0.64, 95% CI ¼
0.48–0.85).33 Of interest, this variant was consistently
associated with lung cancer risk at our discovery stage
(OR ¼ 0.82, 95% CI ¼ 0.70–0.96, p ¼ 0.011; Table S6). In
the samples examined during the discovery stage, the iden-
tified low-frequency variant rs9469031 (MAF ¼ 0.036 in
control subjects) was in low LD with the common variant
rs2736158 (MAF ¼ 0.139 in control subjects), given that r2
was 0.19; however, all of the individuals carrying the
protective allele of rs9469031 also had the protective
allele of rs2736158, yielding a D0 ¼ 1.00 (Table S6). The
association of rs2736158 was abolished after we condi-
tioned on rs9469031 (OR ¼ 0.92, 95% CI ¼ 0.78–1.09,
p ¼ 0.331), whereas the association of rs9469031 changed
modestly (OR ¼ 0.56, 95% CI ¼ 0.39–0.81, p ¼ 0.002).
Collectively, these findings indicate that the association
of the common variant rs2736158 might be driven by
association of the low-frequency variant rs9469031. In
addition, two independent common variants rs3817963
and rs2395185 at 6p21.32 (837 kb and 772 kb away
from rs9469031, respectively) are reported to be associated
with lung cancer risk in Japanese10 and Chinese9 popula-
tions, respectively. The absence of LD between the low-
frequency variant and these two common variants (r2 <
0.01) indicates that the signal of rs9469031 might be
independent from the signals reported in Eastern Asian
populations.
Because there are at least two variants (rs117160266 in
FKBPL and rs9469057 in HSPA1L) in strong LD with015
Table 2. Association between FKBPL, at 6p21.33, and Lung Cancer Risk according to Gene-Based Analysis
Test Stage Variants Included p Valuea
Conditional Analysis
Variants Included (p Value
for Single-Variant Test)
p Value for Gene-Based
Analysisb
SKAT-O discovery rs200847762, rs117160266,
and rs142997752
1.29 3 109 rs200847762 (1.84 3 106) 3.44 3 105
rs117160266 (4.91 3 105) 3.26 3 106
rs200847762 and rs117160266 0.106
replication I rs200847762 and rs117160266c 1.15 3 106 – –
replication II rs200847762 and rs117160266c 5.55 3 104 – –
Burden discovery rs200847762, rs117160266,
and rs142997752
2.00 3 1010 rs200847762 (1.84 3 106) 2.75 3 105
rs117160266 (4.91 3 105) 1.36 3 107
rs200847762 and rs117160266 0.081
replication I rs200847762 and rs117160266c 4.81 3 107 – –
replication II rs200847762 and rs117160266c 9.61 3 104 – –
aAfter adjustment for age, gender, pack years of smoking, and the top principal component (for the discovery stage only).
bAfter additional adjustment for the corresponding lead variant(s).
cThe genotypes of rs9469031 were used here because rs9469031 was highly correlated with rs117160266 at the discovery stage (r2 ¼ 0.96).rs9469031 in BAT2, it is important to determine which is
the causal variant at 6p21.33. BAT2 (also known as
PRRC2A) is in a cluster of HLA-B-associated transcripts
(BAT1-5) in the human major histocompatibility complex
class III region.34 FKBPL (FK506-binding protein-like), a
divergent member of the immunophilin family, is impli-
cated in the regulation of tumor growth and angiogenesis
and might act as a cancer prognostic marker and a thera-
peutic target.35,36 HSPA1L encodes heat-shock 70-kDa pro-
tein 1-like, which in combination with other heat-shock
proteins stabilizes existing proteins against aggregation
and protects against DNA damage.37 Functional variants
in HSPA1B have been associated with lung cancer risk
and survival.38 RNA-seq data from TCGA indicated that
BAT2 and FKBPL were upregulated in 84.1% (p ¼ 8.50 3
1016) and 91.6% (p¼ 2.253 1018) of lung tumor tissues,
respectively, and HSPA1L was significantly downregulated
(79.4%, p ¼ 1.56 3 1010) (Figure S9). We also assessed
the clinical relevance of these three genes and did not
find significant associations between the mRNA levels
and lung cancer survival (Figure S10). Of interest, for
rs9469057 at HSPA1L, the substitution p.Ala8Pro is pre-
dicted to be damaging (Table S7). Nevertheless, gene-based
analysis supported the conclusion that FKBPL, which has
two independent risk-related variants, might be the lung-
cancer-associated gene at 6p21.33.
The LD of common variants that were associated with
lung cancer risk at chromosome 6 from 26–34 Mb (across
6p22.2–6p21.31) has been reported to extend over long
distances.6 Genetic variants in this region have been asso-
ciated with multiple diseases or traits, especially those
relating to inflammation and/or immune-related diseases,
such as allergies,39 chronic hepatitis B virus infection,40
ulcerative colitis,41 multiple myeloma,42 and diffuse largeThe AmB cell lymphoma.43 Consistent with this finding, more
than 100 low-frequency or rare variants in this region
were observed to be associated with lung cancer risk
(p < 0.01) in our study, yielding an obvious peak on the
Manhattan plot (Figure S4). In addition to the two
independent 6p21.33 loci that were described above, we
also found another promising low-frequency variant:
rs2298090 inHIST1H1E at 6p22.2. p.Lys152Arg, the amino
acid change resulting from this variant, is predicted to be
damaging (Table S7). HIST1H1E encodes a member of the
linker histone H1 family, which interacts with linker
DNA between nucleosomes and functions in the compac-
tion of chromatin into higher-order structures.44 TCGA
RNA-seq data showed that the mRNA levels of HIST1H1E
were higher in lung tumors than in the paired normal tis-
sues (83.2%, p ¼ 2.12 3 107; Figure S9); however, the
mRNA levels of HIST1H1E were not associated with lung
cancer prognosis (Figure S10).
The variant rs6141383 in BPIFB1 localizes to 20q11.21,
a region that has not been reported to be associated with
lung cancer susceptibility. As predicted, the substitution
p.Val284Met is damaging to BPIFB1 (Table S7). BPIFB1
(or LPLUNC1) is a secretory protein that is predominantly
present in lung tissues and is present at low levels in other
organs.45 BPIFB1 has been implicated in host innate
immune defenses against pulmonary infection46 and in
the pathogenesis of chronic lung diseases, such as cystic
fibrosis and interstitial lung disease.47 Previous studies
revealed that BPIFB1, which is downregulated in nasopha-
ryngeal carcinoma (NPC),48 can inhibit inflammation and
NPC growth by downregulating the STAT3 pathway.49
BPIFB1 was also significantly downregulated in lung
tumors (67.3%, p ¼ 0.0025; Figure S9), which is consistent
with the prediction that the lung-cancer-associated riskerican Journal of Human Genetics 96, 832–840, May 7, 2015 837
allele of rs6141383 damages BPIFB1. However, high
mRNA levels were associated with poor prognosis in
individuals with lung cancer (p ¼ 0.013; Figure S10),
possibly suggesting that BPIFB1 has dual roles in the
development and progression of lung cancer. Although
the role of BPIFB1 in lung carcinogenesis is limited, these
findings indicate that BPIFB1 might constitute part of
the protective immunity shield that overlies pulmonary
inflammation.
In the current study, we identified three low-frequency
variants that were associated with lung cancer risk in Chi-
nese populations; together with recent findings based on
populations of European ancestry, these results show that
low-frequency variants also contribute to lung cancer
susceptibility. In particular, our results reveal that lung
cancer susceptibility loci across 6p22.2–6p21.31, which
have been reported in populations of European ancestry,
are also present in East Asian populations and that
FKBPL, for which two independent risk-related variants
were found, might be a lung-cancer-associated gene at
6p21.33. We also observed a relationship between lung
cancer and BPIFB1 at 20q11.21. These genetic associations,
together with differences in expression in lung cancer tis-
sues, indicate that genes at 6p21.33 and 20q11.21 might
play key roles in lung carcinogenesis.Supplemental Data
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